UY33598A - Imidazopiridazinas sustituidas - Google Patents

Imidazopiridazinas sustituidas

Info

Publication number
UY33598A
UY33598A UY0001033598A UY33598A UY33598A UY 33598 A UY33598 A UY 33598A UY 0001033598 A UY0001033598 A UY 0001033598A UY 33598 A UY33598 A UY 33598A UY 33598 A UY33598 A UY 33598A
Authority
UY
Uruguay
Prior art keywords
compounds
imidazopiridazinas
replaced
angiogenesis
prophylaxis
Prior art date
Application number
UY0001033598A
Other languages
English (en)
Inventor
Klar Ulrich
Koppitz Marcus
Jautelat Rolf
Kosemund Dirk
Bohlmann Rolf
Lienau Philip
Siemeister Gerhard
Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY33598A publication Critical patent/UY33598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Compuestos de imidazopiridazina sustituida de la fórmula general I donde R3, R5 y A son como se definen en la descripción y en las reivindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o angiogenésis, como un único agente o en combinación con otros ngredientes activos.
UY0001033598A 2010-09-10 2011-09-08 Imidazopiridazinas sustituidas UY33598A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP11075022 2011-02-04
EP11170771 2011-06-21
EP11170775 2011-06-21

Publications (1)

Publication Number Publication Date
UY33598A true UY33598A (es) 2012-04-30

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033598A UY33598A (es) 2010-09-10 2011-09-08 Imidazopiridazinas sustituidas

Country Status (38)

Country Link
US (1) US9255100B2 (es)
EP (1) EP2614063B1 (es)
JP (1) JP5824050B2 (es)
KR (1) KR20140032337A (es)
CN (1) CN103370318B (es)
AP (1) AP3607A (es)
AR (1) AR082946A1 (es)
AU (1) AU2011298844B2 (es)
BR (1) BR112013005679A2 (es)
CA (1) CA2810755A1 (es)
CO (1) CO6720961A2 (es)
CR (1) CR20130102A (es)
CU (1) CU24187B1 (es)
CY (1) CY1117352T1 (es)
DK (1) DK2614063T3 (es)
DO (1) DOP2013000054A (es)
EA (1) EA023420B1 (es)
EC (1) ECSP13012752A (es)
ES (1) ES2568220T3 (es)
HK (1) HK1187623A1 (es)
HR (1) HRP20160360T1 (es)
HU (1) HUE028771T2 (es)
IL (1) IL225058A (es)
MA (1) MA34516B1 (es)
ME (1) ME02389B (es)
MX (1) MX2013002713A (es)
MY (1) MY185139A (es)
NZ (1) NZ607904A (es)
PE (1) PE20131164A1 (es)
PL (1) PL2614063T3 (es)
RS (1) RS54661B1 (es)
SA (1) SA111320735B1 (es)
SG (1) SG188417A1 (es)
SI (1) SI2614063T1 (es)
TW (1) TWI541243B (es)
UY (1) UY33598A (es)
WO (1) WO2012032031A1 (es)
ZA (1) ZA201301756B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HUE052198T2 (hu) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology Inc Heterociklusos protein kináz inhibitorok
EP2825540B1 (en) * 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2889919C (en) * 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
EA201600002A1 (ru) 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт Производные пролекарства замещенных триазолопиридинов
CN105392484A (zh) * 2013-06-13 2016-03-09 拜耳制药股份公司 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2893374T3 (es) * 2014-02-21 2022-02-08 Frost Biologic Inc Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativos
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
WO2017095705A1 (en) * 2015-12-04 2017-06-08 Exxonmobil Research And Engineering Company Emm-28, a novel synthetic crystalline material, its preparation and use
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN109476667B (zh) 2016-07-18 2022-06-28 大学健康网络 Ttk抑制剂的固体形式
ES2901421T3 (es) * 2017-04-11 2022-03-22 Straumann Holding Ag Implante dental
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK23399A3 (en) 1996-08-28 2000-08-14 Pfizer 6,5-hetero-bicyclic derivatives, use thereof and pharmaceutical composition on their base
DK1277754T3 (da) 2000-04-27 2005-11-14 Astellas Pharma Inc Imidazopyridinderivater
BRPI0412689A (pt) 2003-07-14 2006-10-03 Arena Pharm Inc derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
US20090023737A1 (en) 2004-02-12 2009-01-22 Neurogen Corporation Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
PE20070805A1 (es) * 2005-11-10 2007-08-13 Schering Corp Imidazopirazinas como inhibidores de proteinquinasa
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
CN101687873A (zh) * 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
JP5394404B2 (ja) 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
CA2793279A1 (en) 2010-03-18 2011-09-22 Ulrich Klar Imidazopyrazines
JP5824040B2 (ja) 2010-06-01 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピラジン
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821837A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103429591A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
WO2012080236A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821817A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103403006B (zh) 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪

Also Published As

Publication number Publication date
JP2013537174A (ja) 2013-09-30
IL225058A (en) 2017-03-30
CY1117352T1 (el) 2017-04-26
CN103370318A (zh) 2013-10-23
BR112013005679A2 (pt) 2016-05-03
WO2012032031A1 (en) 2012-03-15
DK2614063T3 (en) 2016-04-18
HUE028771T2 (en) 2016-12-28
CR20130102A (es) 2013-04-17
PL2614063T3 (pl) 2016-06-30
MY185139A (en) 2021-04-30
SI2614063T1 (sl) 2016-05-31
TWI541243B (zh) 2016-07-11
EP2614063B1 (en) 2016-01-13
EA023420B1 (ru) 2016-06-30
PE20131164A1 (es) 2013-10-30
AU2011298844B2 (en) 2015-02-19
MA34516B1 (fr) 2013-09-02
ME02389B (me) 2016-09-20
AP2013006790A0 (en) 2013-04-30
ECSP13012752A (es) 2014-01-31
CO6720961A2 (es) 2013-07-31
CU24187B1 (es) 2016-07-29
DOP2013000054A (es) 2013-07-31
EP2614063A1 (en) 2013-07-17
CU20130033A7 (es) 2013-08-29
KR20140032337A (ko) 2014-03-14
HK1187623A1 (zh) 2014-04-11
AP3607A (en) 2016-02-26
NZ607904A (en) 2015-02-27
US9255100B2 (en) 2016-02-09
MX2013002713A (es) 2013-05-22
CN103370318B (zh) 2016-04-20
SA111320735B1 (ar) 2015-10-21
RS54661B1 (en) 2016-08-31
AR082946A1 (es) 2013-01-23
SG188417A1 (en) 2013-04-30
CA2810755A1 (en) 2012-03-15
JP5824050B2 (ja) 2015-11-25
ES2568220T3 (es) 2016-04-28
AU2011298844A1 (en) 2013-03-28
ZA201301756B (en) 2016-06-29
HRP20160360T1 (hr) 2016-05-06
TW201211049A (en) 2012-03-16
EA201390339A1 (ru) 2013-09-30
US20130338133A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
UY33598A (es) Imidazopiridazinas sustituidas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
CR20140113A (es) Imidazopiridazinas sustituidas con amino
CR20150455A (es) Imidazopiridazinas sustituidas
NI201700078A (es) Pirazolpiridinaminas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
UY31780A (es) Fenoxibenzamidas sustituidas
UY35848A (es) Tienopirimidinas
CR20160433A (es) Nuevos compuestos
UY37577A (es) Dihidroimidazopiridindionas sustituidas
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY34630A (es) Imidazopiridazinas sustituidas con amino
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol